Supernus Pharmaceuticals EPS - Earnings per Share 2012-2026 | SUPN
Supernus Pharmaceuticals eps - earnings per share from 2012 to 2026. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
| Supernus Pharmaceuticals Annual EPS | |
|---|---|
| 2025 | $-0.68 |
| 2024 | $1.32 |
| 2023 | $0.02 |
| 2022 | $1.04 |
| 2021 | $0.98 |
| 2020 | $2.36 |
| 2019 | $2.10 |
| 2018 | $2.05 |
| 2017 | $1.08 |
| 2016 | $1.76 |
| 2015 | $0.28 |
| 2014 | $-0.26 |
| 2013 | $-2.90 |
| 2012 | $-2.72 |
| 2011 | $31.39 |
| Supernus Pharmaceuticals Quarterly EPS | |
|---|---|
| 2026-06-30 | $-1.01 |
| 2026-03-31 | $-0.04 |
| 2025-12-31 | $-0.07 |
| 2025-09-30 | $-0.80 |
| 2025-06-30 | $0.40 |
| 2025-03-31 | $-0.21 |
| 2024-12-31 | $0.27 |
| 2024-09-30 | $0.69 |
| 2024-06-30 | $0.36 |
| 2024-03-31 | $0.00 |
| 2023-12-31 | $0.04 |
| 2023-09-30 | $-0.29 |
| 2023-06-30 | $-0.02 |
| 2023-03-31 | $0.29 |
| 2022-12-31 | $0.44 |
| 2022-09-30 | $0.03 |
| 2022-06-30 | $0.14 |
| 2022-03-31 | $0.43 |
| 2021-12-31 | $0.04 |
| 2021-09-30 | $0.40 |
| 2021-06-30 | $0.43 |
| 2021-03-31 | $0.11 |
| 2020-12-31 | $0.57 |
| 2020-09-30 | $0.74 |
| 2020-06-30 | $0.65 |
| 2020-03-31 | $0.40 |
| 2019-12-31 | $0.61 |
| 2019-09-30 | $0.54 |
| 2019-06-30 | $0.61 |
| 2019-03-31 | $0.34 |
| 2018-12-31 | $0.47 |
| 2018-09-30 | $0.52 |
| 2018-06-30 | $0.57 |
| 2018-03-31 | $0.49 |
| 2017-12-31 | $0.28 |
| 2017-09-30 | $0.29 |
| 2017-06-30 | $0.32 |
| 2017-03-31 | $0.19 |
| 2016-12-31 | $0.32 |
| 2016-09-30 | $1.18 |
| 2016-06-30 | $0.18 |
| 2016-03-31 | $0.08 |
| 2015-12-31 | $0.14 |
| 2015-09-30 | $0.08 |
| 2015-06-30 | $0.04 |
| 2015-03-31 | $0.02 |
| 2014-12-31 | $0.10 |
| 2014-09-30 | $-0.06 |
| 2014-06-30 | $0.08 |
| 2014-03-31 | $-0.38 |
| 2013-12-31 | $-0.63 |
| 2013-09-30 | $-0.78 |
| 2013-06-30 | $-0.89 |
| 2013-03-31 | $-0.60 |
| 2012-12-31 | $4.49 |
| 2012-09-30 | $-0.55 |
| 2012-06-30 | $-0.61 |
| 2012-03-31 | $-6.05 |
| 2011-12-31 | $40.14 |
| 2011-09-30 | $-6.64 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $2.409B | $0.719B |
| Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $44.899B | 17.67 |
| BridgeBio Pharma (BBIO) | United States | $13.352B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $9.749B | 24.85 |
| Aspen Pharmacare (APNHY) | South Africa | $4.248B | 0.00 |
| Bausch Health Cos (BHC) | Canada | $2.129B | 1.33 |
| Personalis (PSNL) | United States | $1.687B | 0.00 |
| Taysha Gene Therapies (TSHA) | United States | $1.652B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $1.019B | 9.58 |
| Assembly Biosciences (ASMB) | United States | $0.519B | 24.98 |
| Sol-Gel Technologies (SLGL) | Israel | $0.178B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.043B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |